The aim of this study is to evaluate the efficacy of the addition of Atezolizumab to FOLFOXIRI plus bevacizumab as first line treatment of patients with pMMR and Immunoscore IC-high metastatic colorectal cancer in terms of Progression Free Survival (PFS).
Histologically proven diagnosis of colorectal cancer;
Initially unresectable metastatic colorectal cancer not previously treated with chemotherapy for metastatic disease;
Proficient mismatch repair (pMMR) status in tumour tissue (primary or metastatic), as determined by a local laboratory assay in a CLIA- or similarly certified;
Immunoscore IC-high status in tumour tissue (primary or metastatic), as determined by a sponsor-defined central laboratory (HEGP, AP-HP, INSERM, France).
Radiotherapy to any site within 4 weeks before the study;
Previous adjuvant oxaliplatin-containing chemotherapy;
Previous treatment with bevacizumab;
Prior treatment with CD137 agonists, anti-CTLA4, anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents;
Gruppo Oncologico del Nord-Ovest
Lead sponsor
Hoffmann-La Roche
Collaborator